AFFiRiS AG - Product Pipeline Review

Global Markets Direct’s, ‘AFFiRiS AG - Product Pipeline Review - 2016’, provides an overview of the AFFiRiS AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AFFiRiS AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of AFFiRiS AG

The report provides overview of AFFiRiS AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses AFFiRiS AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features AFFiRiS AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate AFFiRiS AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for AFFiRiS AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding AFFiRiS AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AFFiRiS AG Snapshot 5

AFFiRiS AG Overview 5

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AFFiRiS AG Snapshot 5

AFFiRiS AG Overview 5

Key Information 5

Key Facts 5

AFFiRiS AG - Research and Development Overview 6

Key Therapeutic Areas 6

AFFiRiS AG - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

AFFiRiS AG - Pipeline Products Glance 10

AFFiRiS AG - Clinical Stage Pipeline Products 10

Phase I Products/Combination Treatment Modalities 10

AFFiRiS AG - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

AFFiRiS AG - Drug Profiles 12

ATH-03 12

Product Description 12

Mechanism of Action 12

R&D Progress 12

ATH-04 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

ATH-06 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

PD-01 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

PD-03 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

AD-05 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ATH-05 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

PD-04 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Vaccine for Allergic Rhinitis and Asthma 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Vaccine for Huntington's Disease 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Vaccine for Type 2 Diabetes 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Vaccine to Target C5a for Alzheimer's Disease 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Vaccine to Target PCSK9 for Hypercholesterolemia 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

AFFiRiS AG - Pipeline Analysis 26

AFFiRiS AG - Pipeline Products by Target 26

AFFiRiS AG - Pipeline Products by Route of Administration 27

AFFiRiS AG - Pipeline Products by Molecule Type 28

AFFiRiS AG - Recent Pipeline Updates 29

AFFiRiS AG - Dormant Projects 31

AFFiRiS AG - Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

AFFiRiS AG, Key Information 5

AFFiRiS AG, Key Facts 5

AFFiRiS AG - Pipeline by Indication, 2016 7

AFFiRiS AG - Pipeline ...

List of Tables

AFFiRiS AG, Key Information 5

AFFiRiS AG, Key Facts 5

AFFiRiS AG - Pipeline by Indication, 2016 7

AFFiRiS AG - Pipeline by Stage of Development, 2016 8

AFFiRiS AG - Monotherapy Products in Pipeline, 2016 9

AFFiRiS AG - Phase I, 2016 10

AFFiRiS AG - Preclinical, 2016 11

AFFiRiS AG - Pipeline by Target, 2016 26

AFFiRiS AG - Pipeline by Route of Administration, 2016 27

AFFiRiS AG - Pipeline by Molecule Type, 2016 28

AFFiRiS AG - Recent Pipeline Updates, 2016 29

AFFiRiS AG - Dormant Developmental Projects,2016 31

List of Figures

List of Figures

AFFiRiS AG - Pipeline by Indication, 2016 7

AFFiRiS AG - Pipeline by Stage of Development, 2016 8

AFFiRiS AG - Monotherapy ...

List of Figures

AFFiRiS AG - Pipeline by Indication, 2016 7

AFFiRiS AG - Pipeline by Stage of Development, 2016 8

AFFiRiS AG - Monotherapy Products in Pipeline, 2016 9

AFFiRiS AG - Pipeline by Target, 2016 26

AFFiRiS AG - Pipeline by Molecule Type, 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports